Olivier C.
- Country
- France
- Department
- hépatologie
Research Overview
- An Open Label, Phase 2 Study to Evaluate the Effect of A3907 on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults with Primary Sclerosing Cholangitis (PSC)
- Phase III Double-Blind, Randomized, Placebo-Controlled Study of Norursodeoxycholic Acid in Primary Sclerosing Cholangitis Patients
- Efficacy of Bezafibrate in Primary Sclerosing Cholangitis with Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 18 of 61 partner sites.
Specializations
Hepatobiliary Disorders
This investigator specializes in the treatment of primary sclerosing cholangitis (PSC), a progressive liver disease affecting the bile ducts.
- Bile duct inflammation and scarring
- Cholestasis management
- Liver function preservation
Their research explores novel therapeutic approaches for managing PSC-related complications.
Therapeutic Innovation
The investigator focuses on evaluating emerging treatments including norucholic acid, bezafibrate, and norursodeoxycholic acid for PSC patients.
- Novel drug development
- Treatment efficacy assessment
- Disease progression prevention
Their work encompasses both established and experimental therapeutic approaches.
Symptom Management
The investigator has particular interest in addressing pruritus and other quality-of-life impacting symptoms in PSC patients.
- Itch management strategies
- Bile acid modulation
- Clinical stricture evaluation
Their research includes assessment of targeted therapies for specific PSC manifestations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.